Maxvax Biotechnology Limited Liability Company

This study will test a new RSV vaccine in 60 adults aged 20 and older. Researchers want to understand how the vaccine triggers the immune system to create strong antibodies and memory T cells. The goal is to learn how to make RSV vaccines more effective.

This early-stage study tests a new vaccine (MKK900) against respiratory syncytial virus (RSV) in 120 healthy women aged 18 to 49. The main goal is to check if the vaccine is safe and triggers a strong immune response. Participants will receive either the new vaccine or an active …